Skip to main content

Table 8 Limitations of treatment success in first-line ER+, HER2- mBC patients - aromatase inhibitors only – from physician survey (n = 103)

From: Treatment patterns and real world clinical outcomes in ER+/HER2- post-menopausal metastatic breast cancer patients in the United States

 

Not at all substantial

Not at all substantial

Moderately substantial

Substantial

Very substantial

 

n

%

n

%

n

%

n

%

n

%

Efficacy

4

3.9%

8

7.8%

43

41.8%

25

24.3%

23

22.3%

Safety/Tolerability

16

15.5%

24

23.3%

23

22.3%

29

28.2%

11

10.7%

Drug resistance

1

1.0%

12

11.7%

42

40.8%

41

39.8%

7

6.8%

Adherence

13

12.6%

23

22.3%

33

32.0%

24

23.3%

10

9.7%

Financial cost of treatments

14

13.6%

24

23.3%

28

27.2%

28

27.2%

9

8.7%

  1. mBC metastatic breast cancer